OncoHost to Present New Research on Plasma Proteomics-Based Treatment Selection in Melanoma at ESMO 2025

Original source here

‍

BINYAMINA, Israel and CARY, N.C., Oct. 15, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that its latest research has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) 2025 Congress, taking place October 17-21 in Berlin, Germany.

The study, "A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma," explores the potential of the company's PROphet® model—originally developed and validated in non-small cell lung cancer (NSCLC)—to inform treatment selection in melanoma, a setting where biomarkers to guide clinical decisions remain limited.

Poster Presentation

Title: A plasma proteomics-based model optimizes first-line treatment decisions for metastatic melanoma
Presenting Author: Ryan Sullivan, MD, Massachusetts General Hospital, Boston, MA, USA
Session Date & Location: October 18, 2025
Session: Melanoma and other skin tumours
Poster Number: 1680P

Study Highlights and Conclusions

PROphet® is a plasma proteomic platform that leverages a panel of 388 Resistance-Associated Proteins (RAPs) to compute the probability of clinical benefit (CB) and stratify patients as PROphet POSITIVE or PROphet NEGATIVE. In NSCLC, the test has demonstrated predictive value for patient outcomes with anti–PD(L)1-based therapy.

In this real-world prospective observational study, pre-treatment plasma samples were collected from 248 patients with metastatic melanoma treated with anti-PD1 monotherapy (pembrolizumab or nivolumab) or anti-PD1 + anti-CTLA4 combination (ipilimumab + nivolumab) were analyzed.

Key findings include:

• Prognostic power: The PROphet® model successfully stratified melanoma patients, with PROphet POSITIVE patients showing a significant survival advantage over PROphet NEGATIVE patients (HR = 0.42, p < 0.001).
• Predictive for anti-PD1 therapy: The strongest effect was observed in patients treated with anti-PD1 monotherapy, underscoring the model's predictive utility in this setting.
• Independent factor: Multivariate analysis confirmed PROphet® remained significant even after adjusting for LDH, age, sex, and other variables (HR = 0.30, p = 0.04).
• Treatment guidance:
  • PROphet POSITIVE patients (66% of cohort) achieved comparable survival with anti-PD1 monotherapy and anti-PD1 + anti-CTLA4 therapy (HR = 0.9, p = 0.35). This suggests monotherapy may be sufficient, sparing patients unnecessary toxicity from combination regimens.
  • PROphet NEGATIVE patients demonstrated a trend toward improved survival with the combination approach (HR = 0.64, p = 0.065).

"Selecting the right treatment modality for melanoma patients remains a significant clinical challenge," said Michal Harel, PhD, VP Translational Medicine at OncoHost. "Our findings demonstrate how plasma proteomics can provide actionable insights that inform treatment decisions and bring us closer to truly personalized care for patients facing melanoma."

‍

‍